This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be followed for up to 15 years after their last dose of Juno CAR T cells for evaluation of delayed adverse events, presence of persisting CAR T-cell vector sequences, presence of replication-competent retrovirus (RCR) or lentivirus (RCL), and survival.
Study Type
OBSERVATIONAL
Enrollment
4
No drug is administered in this study. Patients who received JCAR017 in a previous trial will be evaluated in this trial for long-term safety and survival.
No drug is administered in this study. Patients who received JCARH125 in a previous trial will be evaluated in this trial for long-term safety and survival.
City of Hope
Duarte, California, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Proportion of patients with adverse events
Time frame: 15 years from last treatment
Proportion of patients with detectable viral vector sequences
Time frame: 15 years from last treatment
Proportion of patients with detectable RCR or RCL
Time frame: 15 years from last treatment
Overall survival
Time frame: 15 years from last treatment
Progression-free survival
Time frame: 15 years from last treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.